These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38554057)

  • 1. Phase II Trial of the Impact 0.5% Povidone-Iodine Nasal Spray (Nasodine®) on Shedding of SARS-CoV-2.
    Friedland PL; Tucker S
    Laryngoscope; 2024 Sep; 134(9):3947-3952. PubMed ID: 38554057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial.
    Hasan MJ; Rumi SKNF; Banu SS; Uddin AKMN; Islam MS; Arefin MK
    Trials; 2021 Jan; 22(1):2. PubMed ID: 33397432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone-iodine nasal spray (Nasodine).
    Friedland PL; Polasek TM; Topliss D
    Int Forum Allergy Rhinol; 2024 Sep; 14(9):1525-1528. PubMed ID: 38869489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial.
    Zarabanda D; Vukkadala N; Phillips KM; Qian ZJ; Mfuh KO; Hatter MJ; Lee IT; Rao VK; Hwang PH; Domb G; Patel ZM; Pinsky BA; Nayak JV
    Laryngoscope; 2022 Nov; 132(11):2089-2095. PubMed ID: 34724213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2.
    Frank S; Brown SM; Capriotti JA; Westover JB; Pelletier JS; Tessema B
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1054-1058. PubMed ID: 32940656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial.
    Guenezan J; Garcia M; Strasters D; Jousselin C; Lévêque N; Frasca D; Mimoz O
    JAMA Otolaryngol Head Neck Surg; 2021 Apr; 147(4):400-401. PubMed ID: 33538761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial.
    Khan FR; Kazmi SMR; Iqbal NT; Iqbal J; Ali ST; Abbas SA
    Trials; 2020 Sep; 21(1):785. PubMed ID: 32928313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of the use of nasal and oral antiseptics during a global pandemic.
    Stathis C; Victoria N; Loomis K; Nguyen SA; Eggers M; Septimus E; Safdar N
    Future Microbiol; 2021 Jan; 16(2):119-130. PubMed ID: 33464122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.
    Khan MM; Parab SR; Paranjape M
    Am J Otolaryngol; 2020; 41(5):102618. PubMed ID: 32574894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pilot Study of 0.4% Povidone-Iodine Nasal Spray to Eradicate SARS-CoV-2 in the Nasopharynx.
    Sirijatuphat R; Leelarasamee A; Puangpet T; Thitithanyanont A
    Infect Drug Resist; 2022; 15():7529-7536. PubMed ID: 36575672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
    Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro Nasodine Can be an Effective Antibiofilm Agent for Biofilms that May Cause CRS.
    Hale SJM; Lux CA; Kim R; Biswas K; Tucker S; Friedland P; Mackenzie BW; Douglas RG
    Laryngoscope; 2023 Oct; 133(10):2490-2495. PubMed ID: 36644968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Mouth Rinses and Nasal Spray in the Inactivation of SARS-CoV-2: A Systematic Review and Meta-Analysis of
    Idrees M; McGowan B; Fawzy A; Abuderman AA; Balasubramaniam R; Kujan O
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2).
    Pelletier JS; Tessema B; Frank S; Westover JB; Brown SM; Capriotti JA
    Ear Nose Throat J; 2021 Apr; 100(2_suppl):192S-196S. PubMed ID: 32951446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo evaluation of the virucidal efficacy of chlorhexidine and povidone-iodine mouthwashes against salivary SARS-CoV-2. A randomized-controlled clinical trial.
    Elzein R; Abdel-Sater F; Fakhreddine S; Hanna PA; Feghali R; Hamad H; Ayoub F
    J Evid Based Dent Pract; 2021 Sep; 21(3):101584. PubMed ID: 34479668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore.
    Seneviratne CJ; Balan P; Ko KKK; Udawatte NS; Lai D; Ng DHL; Venkatachalam I; Lim KS; Ling ML; Oon L; Goh BT; Sim XYJ
    Infection; 2021 Apr; 49(2):305-311. PubMed ID: 33315181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework.
    Naqvi SHS; Citardi MJ; Cattano D; Ostrosky-Zeichner L; Knackstedt MI; Karni RJ
    J Otolaryngol Head Neck Surg; 2020 Oct; 49(1):77. PubMed ID: 33109269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Trial.
    Winchester S; Castellarnau A; Jabbar K; Nadir M; Ranasinghe K; Masramon X; Kinghorn GR; John I; Paull JRA
    Pharmaceutics; 2024 Sep; 16(9):. PubMed ID: 39339209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.